Tango Therapeutics, Inc. 4

Director John B. Ketchum received grants of 4,000 RSU-based common shares and a stock option for 25,000 shares of Tango Therapeutics, Inc. stock at a $20.22 exercise price on June 5, 2026.

On June 5, 2026, Tango Therapeutics director John B. Ketchum received equity compensation consisting of 4,000 shares of common stock in the form of time-based restricted stock units and a stock option for 25,000 shares with a $20.22 exercise price, both reported as grants under transaction code “A.” The RSUs will vest in full on the earlier of June 5, 2027 or the next annual stockholders’ meeting, subject to his continued service, while the option will vest in 12 equal monthly installments beginning July 5, 2026 over one year. Following these awards, Ketchum directly holds 24,937 shares of Tango Therapeutics common stock, and the new option grant gives him additional contingent rights to acquire 25,000 shares, indicating a routine but meaningful refresh of his director-level equity incentives rather than an open‑market purchase or sale.

Filing Facts

CIK

1819133

Ticker

TNGX

Form

4

Source Type

sec

Accession

0001193125-26-262227

Alert Tier

5